Ascendis’s healthy appetite

New deals put the company on investor radar screens.

This article was first published in the latest issue of the Moneyweb Investor. To read the magazine click here.

South African pharmaceutical giant Aspen had better start looking over its shoulder: Ascendis Health, which listed on the JSE in 2013 aims to reach Aspen’s size within ten years. 

It’s a big ask considering Aspen has a market capitalisation of R162 billion while Ascendis (ASC) is a fraction of that at R6.9 billion.

It might have been easy to dismiss this goal as part of the seemingly endless energy that emanates from Ascendis’s irrepressible CEO Karsten Wellner, if it wasn’t for two sit-up-and-pay-attention acquisitions.

The company recently announced the R7.3 billion acquisition of two Europe-based companies, generic manufacturer Remedica and sports nutrition business Scitec which will provide the group with two additional growth platforms in Europe.

Remedica, which is based in Cyprus, will complement Ascendis’s existing pharmaceutical business and increase its pharmaceutical footprint in Europe, says Andre Bekker, investment analyst at Avior Capital Markets.

The acquired facilities also have spare capacity to take on the majority of Ascendis’s existing Farmalider business’ manufacturing which is currently outsourced in Spain. “This will support growth in overall margins,” Bekker says.

Scitec Nutrition, which is Europe’s third largest sports nutrition business will serve as a platform for Ascendis’s consumer business in central Europe.

These deals – which followed on from the acquisitions of medical devices firms Respiratory Care Africa (2014) and The Scientific Group (2014); Koi Country (2014) and Spanish generics manufacturer Farmalider (2015), as well as six products from Arctic Health Care (2014) – will change the face of the company, he says.

The investment community largely ignored Ascendis when it first listed. At the time the company had stated its intention of building a multinational healthcare company with three pillars: consumer brands, pharma-med and phyto-vet. It had been cobbled together from about ten smallish acquisitions and had an annualised turnover of R1.6 billion ahead of the listing.

But along with the rapid fire acquisitions and some decent results, it was the passion the CEO – Dr Wellness as some in the media call him – brought to the job that made him hard to miss. Educated in Germany with a doctorate on economics (his thesis was on the impact of economic sanctions in SA), he says he “lives wellness”.

It sounds trite, but he thrives on this job. “A good business with good products and lots of passion is better than a business with great products and no passion,” he says. “It’s the same as competing in the Iron Man. You can’t just show up – this race is 70% mental – it takes passion and determination to complete it.”

It was this passion, coupled with his 18 years of experience with the global healthcare company Fresenius that attracted Ascendis founders Cris Dillon and Gary Shayne to him.

“We look for three things in people,” says Dillon. “Passion, genetics [smarts] and a team ethic. We are like a dog sled team. Everyone must pull in the same direction. If one dog pulls to the right, the sled will not move smoothly.”

Coast2Coast, which has a 45% stake in Ascendis, is intimately involved in the strategic direction of the company.

“C2C handles all of our mergers and acquisitions and corporate finance,” says Wellner. This leaves him free to focus on investors, banks and strategy while Ascendis SA MD Cliff Sampson focuses on integration and day-to-day operations. 

The financial support provided by C2C is not to be underestimated. At least 50 investment professionals staff the global deal team. “We have cherry picked the cream of the crop,” says Dillon, “and they are looking for opportunities all over the world.”

The company is also looking for an MD to run their business in Europe. 

In its results for the six months to December Ascendis reported revenue up 40% to R1.9 billion, Ebitda up 50% to R287 million and headline earnings per share (eps) up 37% to 49cps. Of the roughly 300 companies listed on the JSE’s main board for more than two years, only 14 have seen eps growth of +30% a year for the last two years.

Ascendis is one of those companies.

“I was initially a little sceptical about this business. But what has impressed me is that management has executed on everything they said they would,” says Keith McLachlan, fund manager at AlphaWealth.

Others remain a tad puzzled by Ascendis’ focus on integrated healthcare – that is, healthcare for plants, animals and humans.

“Don’t look local,” says McLachlan, “look at a company like Johnson & Johnson which incorporates consumer brands as well as pharmaceuticals and medical devices. This could be an emerging market J&J.”

While J&J may not have a phyto-vet division, it is one that McLachlan is positive about. “This is an underappreciated market segment. People tend not to skimp on products for their gardens and pets, and as their kids grow up, they tend to spend more in these areas.”

International growth

These two acquisitions place Ascendis on a different footing globally. Management has been on a drive to acquire large platform businesses (onto which smaller bolt-on acquisitions can be added) in Europe, specifically Spain and Eastern Europe.

The acquisitions provide that drive with considerable impetus. While the stated intention was to grow offshore earnings to 30% of the total, earnings from Remedica and Scitech (€23 million and €16 million) will push the group’s offshore earnings from 20% to 50% of the total.

“At least 60% of our cost of goods is exposed to rand volatility. These deals are important in that they provide a natural hedge to our import requirements and revenue stream,” Wellner says.

The company has embarked on a capital raising exercise to fund the acquisitions, which should be complete by August.

It will take until the end of the year to close up the deals and tidy up the finance, says Dillon. After which Ascendis could be open for deals in the New Year.

To buy or not to buy

Both McLachlan and Bekker believe that there is upside in the share price, which at the time of writing was R23.12.

Please consider contributing as little as R20 in appreciation of our quality independent financial journalism.

AUTHOR PROFILE

COMMENTS   0

You must be signed in to comment.

SIGN IN SIGN UP

LATEST CURRENCIES  

USD / ZAR
GBP / ZAR
EUR / ZAR
BTC / USD

The Budget Speech explained
Moneyweb’s 2020 national budget offering, including infographics and audio ratings, as well as past budget coverage....

The Investor Issue 48
Separating out the noise from useful information in the markets is not easy. The trick to staying the course is to keep an eye on ...

The Investor Issue 47
Some people intuitively understand that investing for future gain is a long-term process that cannot be rushed. The management of ...

The Investor Issue 46
While US innovation soars and its tech listings continue at a ferocious pace, SA has no real plan for how to embrace the 4th Indus...

The Investor Issue 45
As the investment world falls more and more in love with the simplicity that ETF investing offers, index providers are realising t...

The Investor Issue 44
Company financial statements are the last line of defence for investors wanting to protect their investments. But these cannot alw...

The Investor Issue 43
What makes one CEO great and another mediocre? The Moneyweb Investor ponders this and other leadership questions in the latest iss...

The Investor Issue 42
Stagnant economic growth and questionable economic policy is hampering the development of mid-sized - and investible - businesses ...

The Investor Issue 41
If you are one of those people who invests more energy into your credit card or medical aid rewards programme than you do your ret...

The Investor Issue 40
Volatility in global markets is higher than it has been in years, giving investors the jitters. Some 'experts' are suggesting a re...

The Investor Issue 39
From lessons from Buffet to building your own crypto-portfolio (a risky endeavour by anyone's standards), this issue of The Moneyw...

The Investor Issue 38
They say the art of investing is to ignore the short-term noise and focus on attaining long-term goals. That's true, but that does...

The Investor Issue 37
Getting the economy on the correct footing requires that everyone pulls their weight. Our writers this month have gone above and b...

The Investor Issue 36
The past year is littered with train wrecks like Steinhoff, SAA and Eskom. But there is real sense of ‘back to business’ in So...

The Investor Issue 35
Stock markets are soaring, but productivity is not. Innovation continues, but leads to fewer new jobs. And the great and the good ...

The Investor Issue 34
South Africans are fed up with corruption, or anything that has even a whiff thereof, as JSE rockstar Naspers is currently experie...

The Investor Issue 33
As the year races towards its close, investors will be forgiven for feeling a little breathless. The British WWII propaganda phras...

The Investor Issue 32
Anyone would think that getting an economy moving is rocket science. It's actually not. It requires single-minded commitment. Whil...

The Investor Issue 31
We examine the opportunities of forex trading, the best unit trusts, e-commerce at Richemont and more. ...

The Investor Issue 30
Despite what the astrologers say, there are no shortcuts when it comes to successful stock picking. Fundamental analysis counts. T...

INSIDER SUBSCRIPTIONS APP VIDEOS RADIO / LISTEN LIVE SHOP OFFERS WEBINARS NEWSLETTERS TRENDING PORTFOLIO TOOL CPD HUB

Follow us:

Search Articles:
Click a Company: